Alzai Health (TSXV:ALZI) EBITDA Margin %: -5,329.63% (As of Jan. 2026)


TSXV:ALZI Alzai Health Corp TSXV:ALZI
9 GF Score
Price C$0.50
! 1 Warning Sign
View Full Analysis

What is Alzai Health EBITDA Margin %?

Alzai Health TSXV:ALZI 9 EBITDA Margin % is -5,329.63% as of Jan. 2026. GuruFocus rates TSXV:ALZI with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Alzai Health ranks worse than 93.96% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alzai Health's EBITDA for the three months ended in Jan. 2026 was C$-1.44 Mil. Alzai Health's Revenue for the three months ended in Jan. 2026 was C$0.03 Mil. Therefore, Alzai Health's EBITDA margin for the quarter that ended in Jan. 2026 was -5,329.63%.

Alzai Health  (TSXV:ALZI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Alzai Health EBITDA Margin % Related Terms

Alzai Health EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Alzai Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health EBITDA Margin % Chart

Alzai Health Annual Data
Trend
EBITDA Margin %

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
EBITDA Margin % 0.00 0.00 0.00 0.00 -5,329.63

TSXV:ALZI vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Alzai Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzai Health EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzai Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alzai Health's EBITDA Margin % falls into.


TSXV:ALZI
9GF Score
Alzai Health Corp TSXV:ALZI
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alzai Health's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Alzai Health's EBITDA Margin % for the quarter that ended in Jan. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-1.439/0.027
=-5,329.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -5,329.63% mean?
Alzai Health (TSXV:ALZI) has a EBITDA Margin % of -5,329.63% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alzai Health and its competitors. According to the industry distribution chart, Alzai Health ranks #886 out of 943 companies in the Biotechnology industry, placing it in the top 94%.
Is Alzai Health's EBITDA Margin % too high?
Alzai Health's current EBITDA Margin % is -5,329.63%. Based on the distribution chart, Alzai Health ranks #886 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzai Health ranks #886 out of 943 companies for EBITDA Margin %. This places Alzai Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alzai Health and its competitors. Alzai Health's current EBITDA Margin % is -5,329.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (TSXV:ALZI) has a current EBITDA Margin % of -5,329.63%. The current EBITDA Margin % is -5,329.63%. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alzai Health (TSXV:ALZI), the current EBITDA Margin % is -5,329.63% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for TSXV:ALZI

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price